This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Shariat, S. F. Articles by Slawin, K. M. Search for Related Content PubMed PubMed Citation Articles by Shariat, S. F. Articles by Slawin, K. M. Social Bookmarking                            What's this?

Association of Preoperative Plasma Levels of Vascular Endothelial Growth Factor and Soluble Vascular Cell Adhesion Molecule-1 With Lymph Node Status and Biochemical Progression After Radical Prostatectomy

From the Baylor Prostate Center and the Division of Male Reproductive Medicine and Surgery of the Scott Department of Urology; Department of Pathology and Molecular and Cellular Biology, Baylor College of Medicine; The Methodist Hospital, Houston; and Department of Urology, University of Texas Southwestern Medical School, Dallas, TX.

Address reprint requests to Kevin Mark Slawin, MD, Scott Department of Urology, Baylor College of Medicine, 6560 Fannin St, Ste 2100, Houston, TX 77030; e-mail: kslawin{at}www.urol.bcm.tmc.edu

PURPOSE: Angiogenesis is a critical process for cancer progression. We tested whether elevated circulating levels of the angiogenesis-related markers vascular endothelial growth factor (VEGF) and/or soluble vascular cell adhesion molecule-1 (sVCAM-1) are associated with prostate cancer diagnosis, stage, progression, and metastasis.

PATIENTS AND METHODS: Plasma levels of VEGF and sVCAM-1 were measured on frozen, archival plasma obtained preoperatively from 215 consecutive patients who underwent radical prostatectomy for clinically localized disease, nine men with untreated prostate cancer metastatic to bones, and 40 healthy men without cancer.

RESULTS: Plasma levels of both VEGF and sVCAM-1 were highest in patients with bone metastases (P < .001). VEGF levels were higher in patients with clinically localized disease than in healthy controls (P < .001). VEGF levels were elevated in patients with biopsy and final Gleason sum 7 (P = .036 and P = .020, respectively) and extraprostatic extension (P = .047). Higher preoperative VEGF was independently associated with metastases to lymph nodes (P < .001). Both VEGF and sVCAM-1 were independently associated with biochemical progression after adjustment for the effects of standard preoperative features (P = .014 and P = .039, respectively). VEGF remained independently associated with biochemical progression after adjustment for standard postoperative features (P = .019).

CONCLUSION: Plasma levels of VEGF increased incrementally from healthy controls to patients with clinically localized disease to patients with lymph node and skeletal metastases. Higher preoperative VEGF was independently associated with metastases to lymph nodes and biochemical progression after surgery in both pre- and postoperative models. Plasma sVCAM-1 was elevated in men with bone metastases and was associated with biochemical progression in a preoperative model.

S.F.S. is supported by the Austrian Program for Advanced Research and Technology, and V.A.A. is supported by the American Cancer Society (grant No. IRG 93-034-06).

Drs Shariat and Anwuri contributed equally to this study.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Dror Michaelson, M. M. Regan, W. K. Oh, D. S. Kaufman, K. Olivier, S. Z. Michaelson, B. Spicer, C. Gurski, P. W. Kantoff, and M. R. Smith Phase II study of sunitinib in men with advanced prostate cancer Ann. Onc., May 1, 2009; 20(5): 913 - 920. [Abstract] [Full Text] [PDF]

				S. F. Shariat, J. A. Karam, J. Walz, C. G. Roehrborn, F. Montorsi, V. Margulis, F. Saad, K. M. Slawin, and P. I. Karakiewicz Improved Prediction of Disease Relapse after Radical Prostatectomy through a Panel of Preoperative Blood-Based Biomarkers Clin. Cancer Res., June 15, 2008; 14(12): 3785 - 3791. [Abstract] [Full Text] [PDF]

				R. S. Svatek, J. A. Karam, C. G. Roehrborn, P. I. Karakiewicz, K. M. Slawin, and S. F. Shariat Preoperative Plasma Endoglin Levels Predict Biochemical Progression After Radical Prostatectomy Clin. Cancer Res., June 1, 2008; 14(11): 3362 - 3366. [Abstract] [Full Text] [PDF]

				J. Gutierrez, G. E. Konecny, K. Hong, A. Burges, T. D. Henry, P. D. Lambiase, W. Lee Wong, and Y. G. Meng A New ELISA for Use in a 3-ELISA System to Assess Concentrations of VEGF Splice Variants and VEGF110 in Ovarian Cancer Tumors Clin. Chem., March 1, 2008; 54(3): 597 - 601. [Abstract] [Full Text] [PDF]

				D. J. Parekh, D. P. Ankerst, J. Baillargeon, B. Higgins, E. A. Platz, D. Troyer, J. Hernandez, R. J. Leach, A. Lokshin, and I. M. Thompson Assessment of 54 Biomarkers for Biopsy-Detectable Prostate Cancer Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 1966 - 1972. [Abstract] [Full Text] [PDF]

				K. A. Mohamedali, A. T. Poblenz, C. R. Sikes, N. M. Navone, P. E. Thorpe, B. G. Darnay, and M. G. Rosenblum Inhibition of Prostate Tumor Growth and Bone Remodeling by the Vascular Targeting Agent VEGF121/rGel. Cancer Res., November 15, 2006; 66(22): 10919 - 10928. [Abstract] [Full Text] [PDF]

				W. Berry and M. Eisenberger Achieving Treatment Goals for Hormone-Refractory Prostate Cancer with Chemotherapy Oncologist, October 1, 2005; 10(suppl_3): 30 - 39. [Abstract] [Full Text] [PDF]